PEG anti-ICAM monoclonal antibody

Drug Profile

PEG anti-ICAM monoclonal antibody

Alternative Names: BIRR 10/PEG; pegylated anti-ICAM MAb

Latest Information Update: 14 Jun 2001

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 14 Jun 2001 No-Development-Reported for Cancer in European Union (Unknown route)
  • 23 May 1997 Preclinical development for Cancer in European Union (Unknown route)
  • 16 May 1997 Preclinical development for Cancer in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top